Evidence map›Paper›PMID 17974005›Full record

ArticleBMC genomics2007

The full-ORF clone resource of the German cDNA Consortium.

Stephanie Bechtel, Heiko Rosenfelder, Anny Duda, Christian Peter Schmidt, Ute Ernst, Ruth Wellenreuther, Alexander Mehrle, Claudia Schuster, Andre Bahr, Helmut Blöcker and 9 more

Open access · goldAbstract read
In one paragraph

Article in BMC genomics, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 45 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Human Protein-l-isoaspartateBiochemistry · 2022
    Article
  8. TET2 as a tumor suppressor and therapeutic target in T-cell acute lymphoblastic leukemia.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 9 institutions in 1 country.

Stephanie BechtelDepartment of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany. s.bechtel@dkfz-heidelberg.de
Heiko Rosenfelder
Anny Duda
Christian Peter Schmidt
Ute Ernst
Ruth Wellenreuther
Alexander Mehrle
Claudia Schuster
Andre Bahr
Helmut Blöcker
Dagmar Heubner
Andreas Hoerlein
Guenter Michel
Holger Wedler
Karl Köhrer
Birgit Ottenwälder
Annemarie Poustka
Stefan Wiemann
Ingo Schupp
German Cancer Research Center · DEHeidelberg University · DEHeinrich Heine University Düsseldorf · DEQiagen (Germany) · DEDKFZ-ZMBH Alliance · DEHeidelberg Engineering (Germany) · DEHelmholtz Centre for Infection Research · DEMedigene (Germany) · DEScienion (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWith the completion of the human genome sequence the functional analysis and characterization of the encoded proteins has become the next urging challenge in the post-genome era. The lack of comprehensive ORFeome resources has thus far hampered systematic applications by protein gain-of-function analysis. Gene and ORF coverage with full-length ORF clones thus needs to be extended. In combination with a unique and versatile cloning system, these will provide the tools for genome-wide systematic functional analyses, to achieve a deeper insight into complex biological processes.

resultsHere we describe the generation of a full-ORF clone resource of human genes applying the Gateway cloning technology (Invitrogen). A pipeline for efficient cloning and sequencing was developed and a sample tracking database was implemented to streamline the clone production process targeting more than 2,200 different ORFs. In addition, a robust cloning strategy was established, permitting the simultaneous generation of two clone variants that contain a particular ORF with as well as without a stop codon by the implementation of only one additional working step into the cloning procedure. Up to 92 % of the targeted ORFs were successfully amplified by PCR and more than 93 % of the amplicons successfully cloned.

conclusionThe German cDNA Consortium ORFeome resource currently consists of more than 3,800 sequence-verified entry clones representing ORFs, cloned with and without stop codon, for about 1,700 different gene loci. 177 splice variants were cloned representing 121 of these genes. The entry clones have been used to generate over 5,000 different expression constructs, providing the basis for functional profiling applications. As a member of the recently formed international ORFeome collaboration we substantially contribute to generating and providing a whole genome human ORFeome collection in a unique cloning system that is made freely available in the community.

Indexed as

Databases, GeneticGenome, HumanCloning, MolecularCodon, TerminatorComputer SimulationCooperative BehaviorDNA, ComplementaryDNA-Directed DNA PolymeraseDNA PrimersGermanyHumansModels, BiologicalOpen Reading FramesPolymerase Chain ReactionQuality ControlRecombination, GeneticCodon, TerminatorDNA, ComplementaryDNA-Directed DNA PolymeraseDNA Primers

Identifiers

PMID17974005
PMCPMC2213676
OpenAlexW2035116866

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.